Founded Year

2016

Stage

Series D | Alive

Total Raised

$217.3M

Valuation

$0000 

Last Raised

$100M | 10 mos ago

About Amperity

Amperity provides an Intelligent Customer Data Platform empowering global consumer brands to create personalized experiences by leveraging all their customer data.

Amperity Headquarter Location

701 5th Ave 26th Floor

Seattle, Washington, 98104,

United States

206-432-8302

ESPs containing Amperity

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Consumer & Retail / E-Commerce

Customer data platforms help consumer enterprises unify customer data from disparate sources to optimize targeted marketing investments.

Amperity named as Leader among 7 other companies, including Tealium, mParticle, and ActionIQ.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Amperity's Products & Differentiation

See Amperity's products and how their products differentiate from alternatives and competitors

  • Datagrid

    DataGrid is the multi-patented infrastructure that powers all the products in Amperity's Comprehensive Enterprise CDP.

    Differentiation

    + connectors and integrations. We accept customer data in any format - we'll adapt to you. 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Amperity

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Amperity in 4 CB Insights research briefs, most recently on Aug 11, 2021.

Expert Collections containing Amperity

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Amperity is included in 7 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,112 items

T

Tech IPO Pipeline

568 items

a

ad tech

3,639 items

A

Artificial Intelligence

8,694 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

C

Conference Exhibitors

5,302 items

T

Targeted Marketing Tech

432 items

This Collection includes companies building technology that enables marketing teams to identify, reach, and engage with consumers seamlessly across channels.

Amperity Patents

Amperity has filed 13 patents.

The 3 most popular patent topics include:

  • Data management
  • Database management systems
  • Data modeling
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/8/2019

4/19/2022

Database management systems, Data management, Relational database management systems, Statistical classification, Classification algorithms

Grant

Application Date

11/8/2019

Grant Date

4/19/2022

Title

Related Topics

Database management systems, Data management, Relational database management systems, Statistical classification, Classification algorithms

Status

Grant

Latest Amperity News

Let’s build something together: Ex-Lowe’s CFO to join Pfizer while Moderna’s David Meline retires; The CEO-partner party rolls on at Flagship

Apr 14, 2022

David Den­ton → The two ma­jor Covid-19 vac­cine com­peti­tors, Pfiz­er and Mod­er­na, will both have new fi­nance chiefs with­in a week of each oth­er: At Pfiz­er, David Den­ton will suc­ceed 15-year vet Frank D’Ame­lio as CFO on May 2 af­ter three years in charge of fi­nances at home im­prove­ment chain Lowe’s. With Pfiz­er’s M&A wheels al­ways spin­ning, Den­ton left as CFO of CVS Health short­ly af­ter play­ing an in­te­gral role in the ac­qui­si­tion of Aet­na in late 2017. Mean­while, David Meline is call­ing it quits at Mod­er­na, head­ing back in­to re­tire­ment near­ly two years in­to his tenure as CFO and yield­ing the stage to Jorge Gomez on May 9. Be­fore tak­ing the CFO job at den­tal prod­ucts man­u­fac­tur­er Dentsply Sirona in 2019, Gomez was al­so fi­nance chief dur­ing a 13-year run at Car­di­nal Health. Meline had re­tired as Am­gen’s CFO un­til the Mod­er­na po­si­tion opened up. Michelle Wern­er → On the heels of Mar­go Geor­giadis’ ap­point­ment , Flag­ship Pi­o­neer­ing has lined up two more CEO-part­ners , and Michelle Wern­er kicked things off as the new chief ex­ec­u­tive of tR­NA-fo­cused All­tr­na. Since the sum­mer of 2020, Wern­er was No­var­tis On­col­o­gy’s world­wide fran­chise head, sol­id tu­mors, and her Big Phar­ma cre­den­tials al­so ex­tend to Bris­tol My­ers Squibb and to As­traZeneca, where she rose to glob­al fran­chise head in hema­tol­ogy. Short­ly af­ter she de­camped for No­var­tis, Calquence won ap­proval in the EU for adult pa­tients with chron­ic lym­pho­cyt­ic leukemia, a year af­ter the FDA gave it the go-ahead in the same in­di­ca­tion. Michael Sev­eri­no Then, the biotech in­cu­ba­tor made a splash on Wednes­day by en­tic­ing Ab­b­Vie pres­i­dent and vice chair­man Michael Sev­eri­no in­to a CEO-part­ner job for a com­pa­ny to be named lat­er. Be­fore his ar­rival at Ab­b­Vie in 2014, Sev­eri­no closed out his 10 years at Am­gen as SVP, glob­al de­vel­op­ment and cor­po­rate CMO. Our Kyle LaHu­cik has more on each new CEO-part­ner. Nis­han de Sil­va → The white-hot ra­dio­phar­ma space picked up an­oth­er chal­lenger in Oc­to­ber 2021 with Ra­dio­net­ics On­col­o­gy, and the Cri­net­ics spin­out — backed by 5AM Ven­tures and Fra­zier Health­care Part­ners — has found a CEO. Nis­han de Sil­va, the pres­i­dent and COO at Po­sei­da from 2015-18, had helmed AFYX Ther­a­peu­tics and is cur­rent­ly a board mem­ber at Se­lec­ta Bio­sciences. He will al­so sit on the board at Ra­dio­net­ics while lead­ing a team that is pro­ject­ed “to more than dou­ble over the com­ing year,” ac­cord­ing to a re­lease. Paulash Mohsen → Paulash Mohsen is get­ting his first op­por­tu­ni­ty as a CEO at Vesi­gen Ther­a­peu­tics, a Har­vard spin­out whose plat­form tech is dubbed AR­MMs (AR­RDC1 Me­di­at­ed Mi­crovesi­cles). Mohsen spent the last sev­en years as CBO of Yu­man­i­ty, a neu­ro biotech that’s hang­ing on for dear life af­ter lay­ing off 60% of the work­force. Yu­man­i­ty’s pipeline for­tunes have soured be­cause of a par­tial clin­i­cal hold on its lead Parkin­son’s can­di­date, and while the com­pa­ny ex­plores its op­tions to stay afloat, Mohsen has jumped ship to a com­pa­ny that launched in Ju­ly 2020 with help from Leaps by Bay­er and Morn­ing­side Ven­tures. → Mario David Saltarel­li is step­ping in­to atai Life Sci­ences plat­form com­pa­ny GA­BA Ther­a­peu­tics as CEO and CMO, suc­ceed­ing co-founder Ian Massey. Saltarel­li takes over the helm — as the com­pa­ny is en­ter­ing Phase II stud­ies in anx­i­ety, de­pres­sion and oth­er neu­ro­log­i­cal in­di­ca­tions for its lead com­pound — with a wealth of ex­pe­ri­ence from ex­ec roles at Neu­ron23 (CEO), En­tra­da Ther­a­peu­tics (CMO), Sytim­mune (CMO), An­nex­on Bio­sciences (CMO) and Mallinck­rodt (CSO). This is all on top of oth­er stints at Pfiz­er, Shire, Ver­tex, Alex­ion and Ab­bott. Ran­na Parekh → The Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter will wel­come Ran­na Parekh as chief di­ver­si­ty, eq­ui­ty and in­clu­sion of­fi­cer on May 31. Parekh comes from the Amer­i­can Col­lege of Car­di­ol­o­gy in Wash­ing­ton, where she was the or­ga­ni­za1tion’s first chief di­ver­si­ty and in­clu­sion of­fi­cer, and she’s al­so held DEI lead­er­ship posts at the Amer­i­can Psy­chi­atric As­so­ci­a­tion. Jo­erg Horn­stein → Jo­erg Horn­stein has bolt­ed from AC Im­mune to be­come CFO and head of cor­po­rate func­tions for Lund­beck, which pro­vid­ed a fore­taste of the in­dus­try-wide staff cuts we’re see­ing to­day by slash­ing 300 jobs and shut­ter­ing its fa­cil­i­ty in In­dia. Horn­stein had han­dled fi­nances at AC Im­mune since 2017 and al­so spent 12 years in mul­ti­ple lo­ca­tions at Mer­ck KGaA. As for Horn­stein’s re­place­ment at the Swiss neu­ro biotech, Chris Roberts will pinch-hit as in­ter­im CFO and has been pro­mot­ed to VP, fi­nance. Roberts joined An­drea Pfeifer’s crew as an as­so­ciate VP in 2017 af­ter more than a decade at Ernst & Young. AC Im­mune al­so made two oth­er lead­er­ship moves with Howard Dono­van as chief HR of­fi­cer and the pro­mo­tion of Ju­lian Snow to VP, US fi­nance & cor­po­rate de­vel­op­ment. Dono­van piv­ots here from the World Eco­nom­ic Fo­rum, where he was head of peo­ple and cul­ture part­ners, peo­ple ser­vices and glob­al re­ward. As with Roberts, Snow start­ed at AC Im­mune five years ago, fill­ing the role of as­so­ciate VP, fi­nan­cial re­port­ing. Gi­na Con­syl­man → Gi­na Con­syl­man has land­ed at Cyrus Moza­yeni-led Vedere Bio II from blue­bird bio as CFO. Con­syl­man starts anew quick­ly at the oc­u­lar gene ther­a­py play­er, which de­buted in May 2021 with a $77 mil­lion Se­ries A, af­ter a dire quar­ter­ly fil­ing co­in­cid­ed with  her de­par­ture from blue­bird bio. Con­syl­man joined blue­bird just eight months ago af­ter sev­en years as CFO of Iron­wood, which has had its own set of ob­sta­cles with its pipeline and saw CEO Mark Mal­lon leave for NeoGe­nomics last year. John Frank → DNA se­quenc­ing pow­er­house Il­lu­mi­na has poached John Frank from Mi­crosoft, nam­ing him chief pub­lic af­fairs of­fi­cer. Frank, whose first day will be April 18, wraps up a 28-year ca­reer with the tech gi­ant, start­ing out as a se­nior at­tor­ney and as­cend­ing to deputy gen­er­al coun­sel & chief of staff. Since March 2020, Frank has tak­en on the role of VP, Unit­ed Na­tions af­fairs and in­ter­na­tion­al or­ga­ni­za­tions. Sam Jack­son → Sit­ting pret­ty with a $100 mil­lion fi­nanc­ing round just a cou­ple weeks ago and tar­get­ing LRRK2 and TYK2, CNS-fo­cused Neu­ron23 has tapped Sam Jack­son as CMO. Jack­son hails from an­oth­er neu­ro play­er, Alec­tor, where he held the same po­si­tion and where for­mer Pas­sage Bio ex­ec Gary Ro­mano will soon re­place him. Jack­son is a Genen­tech and Am­gen vet who was al­so the CMO of Alka­h­est. Raf­faele Baf­fa → Raf­faele Baf­fa has signed on to be CMO at CARs­gen, which is at­tempt­ing to wedge its way in­to the BC­MA CAR-T space with CT053 for mul­ti­ple myelo­ma. Baf­fa piv­ots to CARS­gen from Zio­pharm On­col­o­gy ( now known as Alaunos af­ter the ac­tivist at­tack dust has set­tled), where he was CMO and EVP of R&D. The Sanofi and Pfiz­er vet has al­so been CMO of Servi­er and VP, ther­a­peu­tic area head of on­col­o­gy, glob­al clin­i­cal de­vel­op­ment at Shire. → Jan Pinkas has been el­e­vat­ed to CSO of Pyx­is On­col­o­gy as Ronald Herb­st parts ways with the Pfiz­er ADC spin­out. Last Au­gust, Pinkas joined Pyx­is — which hit Nas­daq the fol­low­ing Oc­to­ber on the strength of a $168 mil­lion IPO — as SVP, pre­clin­i­cal R&D af­ter a two-year stint at Ma­gen­ta Ther­a­peu­tics as SVP, trans­la­tion­al sci­ences. He al­so had a num­ber of re­spon­si­bil­i­ties over a 12-year pe­ri­od at Im­muno­Gen, name­ly VP, trans­la­tion­al R&D. Ravi Rao → Eli Lil­ly im­munome­tab­o­lism part­ner Sit­ryx Ther­a­peu­tics out of Ox­ford has se­lect­ed Ravi Rao as CMO. Rao — a for­mer Glax­o­SmithK­line ex­ec in im­munol­o­gy and spe­cial­ty med­i­cines who was al­so a group med­ical di­rec­tor, im­munol­o­gy clin­i­cal de­vel­op­ment with Roche — was head of R&D and CMO at So­bi be­fore choos­ing a dif­fer­ent path here at GSK-backed Sit­ryx. An­ders Ull­man has since tak­en over Rao’s old posts at So­bi. Mikael Elias­son → Helmed by Stan­ford’s Amit Etkin, psy­chi­a­try start­up Al­to Neu­ro­science has looked to­ward Genen­tech/Roche to ap­point Mikael Elias­son as COO. Elias­son, who was pre­vi­ous­ly Genen­tech/Roche’s glob­al head of in­no­va­tion in neu­ro­science prod­uct de­vel­op­ment, has al­so been glob­al head of new prod­ucts at No­var­tis. Chris­t­ian Anger­may­er and the folks at Ape­iron In­vest­ment Group led Al­to Neu­ro­science’s Se­ries A round last Oc­to­ber, bring­ing the to­tal raised to $40 mil­lion. → Jotin Marango has left Ap­tose to tack­le the dual roles of CFO and head of cor­po­rate de­vel­op­ment with Ike­na On­col­o­gy, which is part­ner­ing with Bris­tol My­ers on its oral AHR in­hibitor IK-175. Marango had been CFO and CBO at Ap­tose, prompt­ing a lead­er­ship shuf­fle in which CEO William Rice is pick­ing up the slack as chief ac­count­ing of­fi­cer and VP of fi­nance Janet Clen­nett “will as­sume fi­nan­cial re­spon­si­bil­i­ties un­til a per­ma­nent CFO is an­nounced.” Karen Davies → Co-found­ed by Feng Zhang and padding its war chest with an $80 mil­lion Se­ries B last month, CRISPR di­ag­nos­tic play­er Sher­lock Bio­sciences has trained a mag­ni­fy­ing glass on Karen Davies as chief de­vel­op­ment of­fi­cer. For the past decade, Davies has held a se­ries of posts at fel­low di­ag­nos­tic de­vel­op­er Quidel — from 2017-20 she was VP of in­stru­ment sys­tems, and since 2020 she served as VP of busi­ness trans­for­ma­tion. Aman­da Mur­phy → Aman­da Mur­phy has re­signed from her role as CFO at cell en­gi­neer­ing play­er Max­Cyte, ef­fec­tive April 15. Ron Holtz, the cur­rent SVP and chief ac­count­ing of­fi­cer, will take over as in­ter­im CFO. While Ko­rn Fer­ry helps in the search for a suc­ces­sor, Holtz is re­turn­ing to the role he first held at Max­Cyte from 2005-20. Else­where, Max­Cyte staffer Sean Menar­guez has been bumped up to di­rec­tor, in­vestor re­la­tions. Shabir Hasham → Seek­ing to put a bow on an NDA fil­ing for its Duchenne mus­cu­lar dy­s­tro­phy drug va­morolone by June, San­thera has pro­mot­ed Shabir Hasham to CMO. Hasham left No­var­tis in 2015 to be­come San­thera’s head of med­ical af­fairs EU & RoW, and since 2019 he’s been glob­al de­vel­op­ment pro­gram lead & glob­al head med­ical af­fairs. While with No­var­tis, Hasham was EU med­ical di­rec­tor and glob­al as­so­ciate brand di­rec­tor for the Swiss phar­ma’s neu­ro­science fran­chise. Hasham’s first day as med­ical chief is slat­ed for May 1. Cristi­na Oli­va → Cristi­na Oli­va is mak­ing her way over to Nor­way-based BerGen­Bio, where she’ll serve as CMO. Oli­va hops aboard af­ter a stint as VP, on­col­o­gy and head of on­col­o­gy cen­tre of ex­cel­lence at IQVIA. Oli­va’s ré­sumé in­cludes a star-stud­ded ca­reer with pre­vi­ous roles at Nordic Nanovec­tor, Take­da, GSK and Eli Lil­ly. → Un­der­go­ing a facelift by of­fi­cial­ly re­nam­ing it­self a cou­ple weeks ago, Swedish can­cer out­fit Vivesto — once known as Oas­mia — has pegged Daniel Tes­fa as CMO. Tes­fa had been med­ical di­rec­tor, clin­i­cal and trans­la­tion sci­ence hema­tol­ogy at So­bi since lead­ing on­col­o­gy and hema­tol­ogy for Bay­er in Scan­di­navia from 2018-20. Vivesto will uti­lize Lon­za’s ex­pand­ed site in Nan­sha, Chi­na, strik­ing a deal in late March with the CD­MO to man­u­fac­ture late-stage ovar­i­an can­cer can­di­date Cantrix­il. → Al­liance Phar­ma is lock­ing in Patrick Ben­nett to helm the bio­an­a­lyt­i­cal ser­vices com­pa­ny as CEO, suc­ceed­ing founder Frank Li, who will re­main as pres­i­dent and on the board of di­rec­tors. Ben­nett brings with him ex­pe­ri­ence from his time at PPD Lab­o­ra­to­ries (VP, strat­e­gy and de­vel­op­ment) and Ther­mo Fish­er Sci­en­tif­ic (di­rec­tor of glob­al strate­gic mar­ket­ing). Richard Bar­tram → Pep­tide spe­cial­ist MBX Bio­sciences is pick­ing up for­mer Es­pe­ri­on ex­ec Richard Bar­tram as CFO. Bar­tram served in the same role dur­ing his time at Es­pe­ri­on — help­ing to raise more than $1.2 bil­lion in cap­i­tal. Pri­or to that stint, Bar­tram was with Price­wa­ter­house­C­oop­ers. → Vaxxas, the com­pa­ny that Mer­ck teamed up with back in 2020 to tap in­to patch de­liv­ery tech, has named Dan Devine as CBO and gen­er­al coun­sel. Devine joins the Bris­bane, Aus­tralia-based com­pa­ny with ex­pe­ri­ence from his roles at Pfiz­er, Pa­trys and Mesoblast. James Gru­ber → James Gru­ber has been named CFO at Alkin­di Sprin­kle mak­er Eton Phar­ma­ceu­ti­cals, tak­ing over the po­si­tion from Wil­son Trout­man, who will re­tire at the end of May. Gru­ber most re­cent­ly served as US con­troller at Hori­zon Ther­a­peu­tics and he al­so spent more than a decade work­ing in var­i­ous fi­nan­cial po­si­tions at Ab­bott. Lib­bie Mansell → As the cal­en­dar flipped to 2022, Javier Szwar­cberg was named CEO of Spruce Bio­sciences, and now the Mike Grey-chaired biotech fo­cused on rare en­docrine dis­or­ders has brought in Lib­bie Mansell as chief reg­u­la­to­ry and qual­i­ty of­fi­cer. If it seems like it wasn’t that long ago since Mansell ap­peared in Peer Re­view, you’re right: Six months ago she joined NFLec­tion Ther­a­peu­tics as SVP of glob­al reg­u­la­to­ry af­fairs & qual­i­ty as­sur­ance, but it’s on to the next chal­lenge. Mansell was al­so part of the AskBio team as SVP of reg­u­la­to­ry af­fairs. → Nau­tilus Biotech­nol­o­gy — backed by Paul Allen and Jeff Be­zos and set­ting sail for Nas­daq via one of Per­cep­tive’s blank-check com­pa­nies last year — has signed on Gwen Weld as chief peo­ple of­fi­cer and Sheri Wilcox as VP of affin­i­ty reagent de­vel­op­ment. Pri­or to join­ing Nau­tilus, Weld was chief peo­ple of­fi­cer at Am­per­i­ty and for­mer­ly gen­er­al man­ag­er of hu­man re­sources at Mi­crosoft. Mean­while, Wilcox hails from So­ma­Log­ic. where she served as se­nior di­rec­tor of glob­al sci­en­tif­ic en­gage­ment. Be­fore that, she was with Phar­ma­cia. → Ka­ri­na Fedasz, who be­gan her ca­reer at JP Mor­gan and was re­cent­ly the CFO of IDW Me­dia Hold­ings, has been named head of busi­ness de­vel­op­ment at Evofem, the mak­er of con­tra­cep­tive gel Phexxi. In Feb­ru­ary, End­points News’ Beth Sny­der Bu­lik spoke with Evofem CEO Saun­dra Pel­leti­er about a num­ber of top­ics, name­ly Phexxi’s ad cam­paign fea­tur­ing “Schitt’s Creek” star An­nie Mur­phy. Heather Vi­tal → Jo Viney’s Seis­mic Ther­a­peu­tic, us­ing ma­chine learn­ing to de­vel­op im­munol­o­gy drugs and launch­ing with a tec­ton­ic plate-shift­ing $101 mil­lion Se­ries A in Feb­ru­ary, has added two ex­ecs: Er­ic Lar­son (SVP of fi­nance) re­unites with Viney, the CEO of Pan­dion be­fore it was sold to Mer­ck for $1.85 bil­lion last year. Be­fore Lar­son was Viney’s VP of fi­nance, he served as cor­po­rate con­troller for Pro­teosta­sis Ther­a­peu­tics. Af­ter near­ly sev­en years with Bio­gen, Heather Vi­tal (VP of R&D strat­e­gy) jumped to De­ci­phera Phar­ma­ceu­ti­cals as se­nior di­rec­tor of pro­gram lead­er­ship and then moved on to her most re­cent gig as se­nior di­rec­tor, port­fo­lio strat­e­gy and op­er­a­tions for Re­lay Ther­a­peu­tics. → TCR biotech TScan Ther­a­peu­tics has a new VP, fi­nance in Lei­den Dworak, who was pre­vi­ous­ly VP, head of fi­nan­cial plan­ning and analy­sis and busi­ness op­er­a­tions at Avro­bio. Dworak has al­so served as the fi­nance lead for glob­al vac­cines busi­ness de­vel­op­ment at Mod­er­na. Lyn­dah Dreil­ing → Cal­i­for­nia-based Ko­r­lym mak­er Cor­cept Ther­a­peu­tics has three new ex­ecs ready to roll: First, Daniel Ein­horn (VP, en­docrine strat­e­gy) was the pres­i­dent of Di­a­betes and En­docrine As­so­ci­ates and med­ical di­rec­tor of Scripps Whit­ti­er Di­a­betes In­sti­tute in San Diego. Amiel Bal­ag­tas (VP, de­vel­op­ment op­er­a­tions) joins the list of Gilead vets at Cor­cept that in­cludes chief HR and com­mu­ni­ca­tions of­fi­cer Amy Flood and chief de­vel­op­ment of­fi­cer William Guy­er, cap­ping off a 23-year ca­reer at the Big Phar­ma as ex­ec­u­tive di­rec­tor, de­vel­op­ment sys­tems. And Lyn­dah Dreil­ing (VP, glob­al on­col­o­gy de­vel­op­ment), who al­so has Gilead ties as se­nior di­rec­tor, clin­i­cal re­search on­col­o­gy, is an Am­gen alum who was re­cent­ly SVP, clin­i­cal de­vel­op­ment with Spec­trum Phar­ma­ceu­ti­cals. → New Jer­sey-based Cel­lec­tar Bio­sciences has two an­nounce­ments this week: Matthew Ha­gan has been ap­point­ed VP, mar­ket­ing and strate­gic al­liances, and David Lasec­ki has joined the on­col­o­gy biotech as ex­ec­u­tive di­rec­tor, strate­gic al­liances. Most re­cent­ly, Ha­gan served as ex­ec­u­tive di­rec­tor, hema­tol­ogy port­fo­lio mar­ket­ing at Bris­tol My­ers. Lasec­ki joins from Heron Ther­a­peu­tics, where he served as se­nior di­rec­tor, on­col­o­gy sales. Michael Mor­ris­sey → Ex­elix­is pres­i­dent and CEO Michael Mor­ris­sey has been named chair­man of the board at Ve­ra Ther­a­peu­tics, step­ping in­to the spot pre­vi­ous­ly oc­cu­pied by Abing­worth’s Kurt von Em­ster. The at­aci­cept de­vel­op­er’s board al­so in­cludes Beth Sei­den­berg from West­lake Vil­lage BioPart­ners and Akero Ther­a­peu­tics CEO An­drew Cheng. → There’s a chang­ing of the guard on the board of di­rec­tors at Cy­to­ki­net­ics, as John Hen­der­son re­places the re­tir­ing Robert Gage. Hen­der­son, a 25-year Pfiz­er vet, has been on the board at Cy­to­ki­net­ics since 2009. Car­di­ol­o­gist and Stan­ford De­part­ment of Med­i­cine chair­man Robert Har­ring­ton has al­so earned a seat on Cy­to­ki­net­ics’ board. Maria Fardis → CRISPR Ther­a­peu­tics has put Maria Fardis’ name for­ward to join the board of di­rec­tors. When her time was up as CEO of Io­vance, Fardis then be­came a ven­ture part­ner at Fra­zier Life Sci­ences. If elect­ed, Fardis would take a seat at a board that in­cludes SR One’s Sime­on George and AskBio’s Kathy High. → Michel De­theux, the pres­i­dent and CEO of iTeos Ther­a­peu­tics, has as­sumed the role of chair­man of the board at French rare bone dis­ease biotech In­noSkel. De­theux co-found­ed iTeos 10 years ago and is al­so chair­man of ONA Ther­a­peu­tics in Barcelona. → Lipocine has brought on Jill Jene and Spy­ros Pa­pa­petropou­los to its board of di­rec­tors. Jene is cur­rent­ly founder and prin­ci­pal of Jene Ad­vi­sors and has pre­vi­ous­ly served as VP and head of cor­po­rate de­vel­op­ment, strat­e­gy, port­fo­lio plan­ning and al­liance man­age­ment at Adamas. Mean­while, Pa­pa­petropou­los is the CMO of Vig­il Neu­ro­sciences and was for­mer­ly SVP, head of de­vel­op­ment at Aca­dia Phar­ma­ceu­ti­cals, CEO of Swan­Bio Ther­a­peu­tics and head of re­search & de­vel­op­ment and CMO at Cavion. AUTHORS Amber Tong Senior Editor As a drug formerly abandoned by Gilead finally looks set to complete its tortuous journey toward FDA approval, GlaxoSmithKline is shelling out $1.9 billion to snap it up. Sierra Oncology gets the credit for salvaging momelotinib — which Gilead first obtained through acquiring YM BioSciences for $510 million, but offloaded in 2018 following late-stage failure — and steering it to a positive Phase III readout earlier this year. Started by the crew that used to run YM, Sierra had paid only $3 million in cash to scoop up the drug, in addition to $192 million in biobucks that Gilead will likely pocket given its success. Keep reading Endpoints with a free subscription Unlock this story instantly and join 139,300+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor When Be Biopharma revealed itself a year and a half ago with $52 million, the Longwood-founded startup was confident about its vision of creating a new class of medicines out of B cells — but not quite sure yet where it would start. The company, which licensed its B cell engineering platform from Seattle Children’s Hospital, had only two employees. Now, with 64 on staff — led by CEO Joanne Smith-Farrell and CSO Rick Morgan, both bluebird vets — Be Bio is finally ready to declare the initial areas of focus. And ARCH Venture Partners is hopping in to lead a $130 million round to lay the long path toward the clinic. Read More Zachary Brennan Senior Editor A group of 30 bipartisan lawmakers sent letters to 7 naloxone manufacturers, calling on them to apply for over-the-counter status for their opioid overdose antidotes and open up supplies further as the opioid crisis continues in the US with record levels of overdoses and deaths. Citing a Massachusetts study that found substantially increased access to naloxone reduced opioid overdose mortality rates by 46%, the senators and representatives called on Pfizer, Teva Pharmaceuticals, Adamis Pharmaceuticals, Akorn, Amphastar Pharmaceuticals, Emergent BioSolutions, and Hikma Pharmaceuticals to “submit applications to make naloxone available over the counter without delay.” Read More Beth Snyder Bulik Senior Editor A handful of prominent oncology pharmas are teaming up on a next-gen diagnostics initiative, with the ambitious vision of testing for all cancer patients. Bayer, GlaxoSmithKline, Novartis and Roche are leading the Precision Cancer Consortium’s drive to open up biomarker testing on a global scale. The new group will try to boost biomarker testing in two ways — by increasing awareness about the value of genomic testing and by working to improve genomic biomarker testing in clinical trials, it said in a press release . Keep reading Endpoints with a free subscription Unlock this story instantly and join 139,300+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor Merck hasn’t sold Zostavax in the US since 2020, but that’s not stopping the lawsuits. Thousands of cases charging Zostavax side effects, efficacy issues and advertising and marketing complaints are still working their way through courts across the country. Estimates of more than 2,000 cases stand, although Merck has been picking up some wins lately. Its most recent dismissal on Tuesday absolved the drugmaker in a class action case in Ohio charging that Merck’s “aggressive marketing campaign” for Zostavax contained false claims around effectiveness and protection duration. It alleged, for instance, that Merck promoted a 51% effectiveness rate, when it was actually lower for older age groups. The lawsuits claimed Merck violated Ohio consumer sales practice laws. Read More Zachary Brennan Senior Editor Almost a week after finalizing its restrictive decision for amyloid-targeted Alzheimer’s drugs, the Centers for Medicare and Medicaid Services (CMS) now appears to be walking back the idea that this decision will have a ripple effect across other accelerated approvals. The comments, made at a Duke-Margolis event Tuesday and covered by multiple media outlets, come as biopharma industry groups have warned in recent days that this CMS coverage decision could create a “dangerous precedent” for drugs approved under the accelerated pathway ⁠— even as CMS has always had the ability to apply its so-called Coverage with Evidence Determination, but never has actually required an additional randomized controlled trial. Read More April 13, 2022 10:43 AM EDT Kyle LaHucik Associate Editor AbbVie president and vice chair Michael Severino is leaving the Chicago-area pharma giant on May 31 to become a CEO-partner at prolific biotech creator Flagship Pioneering in June. He’s the third CEO-partner to be named at the incubator, which is behind the likes of Moderna, in the past six days. He notified the Humira drugmaker on April 8 of his new career ambitions, according to an AbbVie SEC filing Wednesday morning. He’s departing after three and a half years in the president and vice chair posts. Prior to that, he spent nearly five years as CSO. Keep reading Endpoints with a free subscription Unlock this story instantly and join 139,300+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Amperity Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Amperity Rank

You May Also Like

mParticle Logo
mParticle

mParticle puts app owners in full control of their data assets while helping to solve many of the complications that go along with running a mobile business. mParticle not only solves the core challenges of truly creating personalization in mobile but also gives app owners better marketing insights, autonomy from IT cycles, accelerates the launch of new partners/campaigns, and significantly improves app performance & stability. Through a unique approach to mobile data management, mParticle empowers clients to collect, organize and synchronize data, from mobile web and apps.

ActionIQ Logo
ActionIQ

ActionIQ is an enterprise customer data platform that aims to solve the problems marketers face including the flow and scale of data, analytics, and campaigns.

Tealium Logo
Tealium

Tealium enables global businesses to unlock their customer data and create meaningful, relevant customer experiences. The company's customer data platform, comprised of an enterprise tag management solution, omnichannel customer segmentation and action engine, and suite of rich data services, creates a vendor-neutral data foundation that spans web, mobile, offline and IoT.

BlueConic Logo
BlueConic

BlueConic helps brands optimize cross-channel marketing opportunities through improved customer engagement. It offers a SaaS-based online customer engagement platform that leverages a Big Data profile interaction store and machine learning to help marketers synchronize relevant communications across web, mobile and social channels in real time.

Lytics Logo
Lytics

Lytics provides adaptive digital marketing and offers a marketing activation platform that integrates all touch points and surfaces behaviors of customers and prospects to recommend how to best target audiences across Web, mobile, email, and social channels. Through machine learning, its cloud-based software predicts SmartAudience segments and suggests opportunities to marketers to adapt their tactics in real-time.

zeotap Logo
zeotap

Zeotap is a customer intelligence platform that helps companies better understand their customers and predict behaviors, to invest in more meaningful experiences.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.